Apellis Pharmaceuticals, Inc. (APLS)
Market: NASD |
Currency: USD
Address: 100 Fifth Avenue
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Show more
📈 Apellis Pharmaceuticals, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$35.35
-
Upside/Downside from Analyst Target:
99.04%
-
Broker Call:
26
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
25-50%
-
Net Income Growth Range (1Y):
25-50%
-
Revenue Growth Range (1Y):
25-50%
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Apellis Pharmaceuticals, Inc.
| Date | Reported EPS |
|---|
| 2026-02-26 (estimated upcoming) | - |
| 2025-11-03 (estimated upcoming) | - |
| 2025-11-02 (estimated upcoming) | - |
| 2025-07-30 (estimated upcoming) | - |
| 2025-07-29 (estimated upcoming) | - |
| 2025-05-05 | - |
| 2025-05-04 | - |
| 2025-02-28 | -0.29 |
| 2024-11-05 | -0.46 |
| 2024-08-01 | -0.28 |
| 2024-07-31 | -0.28 |
| 2024-05-07 | -0.42 |
| 2024-05-06 | -0.42 |
| 2024-02-27 | -0.73 |
| 2024-02-26 | -0.73 |
| 2023-11-01 | -1.17 |
| 2023-10-31 | -1.17 |
| 2023-07-31 | -1.02 |
| 2023-07-30 | -1.02 |
| 2023-05-04 | -1.56 |
| 2023-05-03 | -1.56 |
| 2023-02-21 | -1.5 |
| 2023-02-20 | -1.5 |
| 2022-11-07 | -1.75 |
| 2022-11-06 | -1.75 |
| 2022-08-08 | -1.46 |
| 2022-08-07 | -1.46 |
| 2022-05-04 | -1.42 |
| 2022-05-03 | -1.42 |
| 2022-02-28 | -1.61 |
| 2022-02-27 | -1.61 |
| 2021-11-08 | -2.28 |
| 2021-11-07 | -2.28 |
| 2021-08-09 | -2.72 |
| 2021-08-08 | -2.72 |
| 2021-04-28 | -2.32 |
| 2021-04-27 | -2.32 |
| 2021-02-25 | 0.93 |
| 2021-02-24 | 0.93 |
| 2020-11-02 | -1.79 |
| 2020-11-01 | -1.79 |
| 2020-07-30 | -1.57 |
| 2020-07-29 | -1.57 |
| 2020-04-29 | -2.29 |
| 2020-04-28 | -2.29 |
| 2020-02-27 | -1.77 |
| 2020-02-26 | -1.77 |
| 2019-11-04 | -1.1 |
| 2019-07-30 | -1.12 |
| 2019-05-06 | -0.87 |
| 2019-02-25 | -0.65 |
| 2018-11-12 | -0.64 |
| 2018-07-30 | -0.61 |
| 2018-04-29 | -0.43 |
| 2018-03-18 | -0.6 |
| 2017-12-20 | -1.37 |
| 2017-11-08 | - |
📰 Related News & Research
No related articles found for "apellis pharmaceuticals".
